Oculis
Oculis Holding AG is a clinical-stage biopharmaceutical company developing topical ophthalmic and neuro-ophthalmic therapeutics, including Privosegtor (OCS-05) for optic neuritis, Licaminlimab (OCS-02) for dry eye disease, and the OCS-01 dexamethasone program, all leveraging the proprietary OPTIREACH® topical delivery platform.
- Company typePublic
- Founded2017
- HeadquartersZug, Switzerland
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Oculis does
Oculis Holding AG is a clinical-stage biopharmaceutical company developing ophthalmic and neuro-ophthalmic therapeutics. Incorporated in Switzerland in 2017 (with predecessor entity dating to 2003) and dual-listed on the U.S. Nasdaq Global Market and Nasdaq Iceland Main Market under ticker OCS, the company is headquartered in Zug, Switzerland, with operating laboratory facilities in Reykjavik, Iceland, and medical affairs activity in the United States. Oculis has no approved products and is currently pre-commercial, with the most recent disclosed quarterly revenue of approximately $0.50M derived from limited operations or collaboration activity rather than product sales.
Oculis firmographics
Firmographics- Name
- Oculis
- Legal name
- Oculis Holding AG
- Website
- https://oculis.com
- Company type
- Public
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Oculis Holding AG is a clinical-stage biopharmaceutical company developing topical ophthalmic and neuro-ophthalmic therapeutics, including Privosegtor (OCS-05) for optic neuritis, Licaminlimab (OCS-02) for dry eye disease, and the OCS-01 dexamethasone program, all leveraging the proprietary OPTIREACH® topical delivery platform.
- Ownership category
- akta.pro rank
Oculis industry classification
Industry- Product category
- Ophthalmic Biopharmaceuticals
- NAICS
- Ophthalmic Goods Manufacturing (339115)
- SIC
- Ophthalmic Goods (3851)
- akta.pro primary industry
- Retina & Vitreous Specialists (HLAKAKAE)
- akta.pro secondary industries
- Ophthalmology Specialty Pharmaceuticals (HLAIACAK), Rare Ophthalmology Disorder Therapies (HLAIAIAK)
Keywords
Where Oculis is headquartered
LocationHeadquarters
- HQ city
- Zug
- HQ country
- Switzerland
- HQ region
- Europe
Offices4 records
Markets served
Oculis business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Pre-Revenue / Pre-Commercial Biopharmaceutical Operations: Oculis is a pre-commercial clinical-stage biopharmaceutical company with no approved products; reported minimal revenue (approximately $0.50 million in a quarter) primarily from limited operations/collaboration. The company's value driver is the late-stage clinical pipeline (Privosegtor, Licaminlimab) intended for eventual commercialization as prescription therapeutics. Once approved, expected revenue would be derived from one-time prescription drug sales (hardware/pharmaceutical product sales) of ophthalmic and neuro-ophthalmic therapies.
Go-to-market motion3 records
Distribution channels2 records
Marketing channels6 records
Oculis product offering
Product offeringCore offering
Oculis is a clinical-stage biopharmaceutical company developing a pipeline of topical ophthalmic drug candidates for retinal, neuro-ophthalmic, and ocular surface diseases, anchored by its proprietary OPTIREACH® cyclodextrin-based topical drug delivery platform. The company is currently advancing three lead assets: Privosegtor (OCS-05), a first-in-class neuroprotective peptoid for optic neuritis and NAION; Licaminlimab (OCS-02), an anti-TNFα biologic eye drop for dry eye disease; and OCS-01, a topical dexamethasone for diabetic macular edema and post-cataract surgery inflammation.
Product overview
Oculis is a clinical-stage biopharmaceutical company offering a single, integrated pipeline of ophthalmic therapeutic candidates rather than a software product suite. Its portfolio is anchored by the proprietary OPTIREACH® topical drug-delivery technology platform, which underpins the company's lead ocular-surface and back-of-the-eye candidates: Privosegtor (OCS-05), a novel peptoid small molecule neuroprotective candidate in development for acute optic neuritis and non-arteritic anterior ischemic optic neuropathy (NAION); Licaminlimab (OCS-02), an anti-TNFα eye drop for dry eye disease formulated using OPTIREACH®; and OCS-01, a topical dexamethasone eye drop being evaluated in the DIAMOND Phase 3 program for diabetic macular edema and post-cataract surgery inflammation and pain.
Differentiator
Problem solved
Functional benefit
Brands
- OPTIREACH®: Proprietary drug delivery technology platform used to develop topical eye drop formulations, including the OCS-01 dexamethasone cyclodextrin-based ophthalmic solution.
- Privosegtor (OCS-05)
- Licaminlimab (OCS-02)
- OCS-01
Products and services
- Privosegtor (OCS-05) A first-in-class novel peptoid small molecule (BN201-class) neuroprotective drug candidate in development for acute optic neuritis, non-arteritic anterior ischemic optic neuropathy (NAION), and multiple sclerosis relapses. It crosses the blood-brain and retinal barriers, has received FDA Breakthrough Therapy and EMA PRIME designations, and holds Orphan Drug designations from both FDA and EMA for acute optic neuritis. PIONEER Phase 3 program and PREDICT-1 trial are in progress.
- Licaminlimab (OCS-02) Anti-TNFα eye drop candidate in development for dry eye disease (DED) and ocular surface inflammation, leveraging the OPTIREACH® delivery platform. A humanized single-chain variable fragment (scFv) antibody neutralizing TNFα with lower molecular weight than a full antibody, paired with a proprietary TNFR1 genetic biomarker enabling 7-fold higher treatment response in biomarker-positive patients.
- OCS-01 Topical dexamethasone eye drop formulation leveraging the OPTIREACH® cyclodextrin-based delivery technology. OCS-01 was being evaluated in the DIAMOND Phase 3 program for diabetic macular edema (DME) and in the OPTIMIZE Phase 3 program for inflammation and pain following cataract surgery. The DME program was discontinued following May 2026 Phase 3 failure.
Quantifiable outcome
- 7-fold increase in treatment response in TNFR1 biomarker-positive DED patients with Licaminlimab vs. vehicle
- +2 more outcomes
Companies that use Oculis
Customer profileSegments4 records
Ideal customer profiles2 records
Oculis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Oculis partnerships and signals
Strategic signalScale indicators12 records
Recent moves9 records
Expansion highlights6 records
Oculis competitors and assessment
Company assessmentPeers
Direct peers
- Iveric Bio: Clinical-to-commercial ophthalmology biopharma (avacincaptad pegol for geographic atrophy) acquired by Astellas for ~$5.9B in 2023; directly comparable late-stage ophthalmology pipeline-stage peer that shared the same SNSP regulatory pathway and was led by executives (Shah) now at Oculis.
- Apellis Pharmaceuticals: Commercial-stage ophthalmology biopharma with Syfovre (pegcetacoplan) for geographic atrophy and Empaveli; a directly comparable back-of-the-eye, complement-mediated disease peer sharing retina specialist channels and KOL relationships.
- Kodiak Sciences: Clinical-stage ophthalmology biopharma developing tarcocimab and other anti-VEGF therapeutics for retinal diseases including DME; directly comparable late-stage retinal-disease pipeline and similarly dependent on intravitreal-vs-non-invasive paradigm.
- Aldeyra Therapeutics: Late-stage clinical biopharma focused on dry eye disease and other immune-mediated ocular diseases (reproxalap); directly comparable DED-focused pipeline with similar regulatory pathway and target prescriber base.
- Outlook Therapeutics: Clinical-stage biopharma developing ONS-5010/Lytenava (bevacizumab) for wet AMD and other retinal indications; comparable small-cap ophthalmology pure-play with similar regulatory and capital-raising profile.
- Adverum Biotechnologies: Clinical-stage gene therapy company targeting wet AMD and diabetic macular edema (DME) with ADVM-022; directly comparable late-stage retinal disease developer targeting the same anti-VEGF / DME market OCS-01 was pursuing.
- REGENXBIO: Clinical/commercial gene therapy company with ABBV-RGX-314 for wet AMD/diabetic retinopathy and a deep ophthalmology pipeline; comparable late-stage retinal disease peer with NAVXpressAAV platform and overlapping KOL/clinical trial footprint.
Emerging players
- Annexon Inc: Clinical-stage biopharma developing neuroprotective/complement therapies for neuroinflammatory and ophthalmic indications including geographic atrophy; partial overlap with Privosegtor's neuroprotective mechanism and orphan neurology/ophthalmology strategy.
Broad incumbents
- Santen Pharmaceutical: Global Japanese ophthalmology incumbent with broad prescription portfolio in DED, glaucoma, and retinal disease; large established peer against whose franchise Oculis's Licaminlimab and OPTIREACH®-enabled products would compete.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Oculis social profiles
Digital presenceOculis compliance and trust
Trust signalCompliance5 records
Oculis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Oculis leadership team
Management profileNumber of profiles
Profiles10 records
Oculis subsidiaries and ownership
Company hierarchySubsidiaries2 records
Oculis funding detail
Funding detailFunding overview
Funding rounds16 records
Investors15 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Oculis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Oculis
What does Oculis do?
Oculis is a clinical-stage biopharmaceutical company developing a pipeline of topical ophthalmic drug candidates for retinal, neuro-ophthalmic, and ocular surface diseases, anchored by its proprietary OPTIREACH® cyclodextrin-based topical drug delivery platform. The company is currently advancing three lead assets: Privosegtor (OCS-05), a first-in-class neuroprotective peptoid for optic neuritis and NAION; Licaminlimab (OCS-02), an anti-TNFα biologic eye drop for dry eye disease; and OCS-01, a topical dexamethasone for diabetic macular edema and post-cataract surgery inflammation.
Is Oculis a public or private company?
Oculis is a public company. It is classified as public and is currently operating.
When was Oculis founded?
Oculis was founded in 2017. It employs 51 to 100 people.
Where is Oculis based?
Oculis is headquartered in Zug, Switzerland, in the Europe region.
How does Oculis make money?
One revenue line is on record: pre-Revenue / Pre-Commercial Biopharmaceutical Operations.
Who are Oculis's main competitors?
Bausch + Lomb is listed as a peer. Direct peers are Iveric Bio, Apellis Pharmaceuticals, Kodiak Sciences, Aldeyra Therapeutics, Outlook Therapeutics, Adverum Biotechnologies and REGENXBIO. Annexon Inc is listed as an emerging player. Santen Pharmaceutical is listed as a broad incumbent.
Does Oculis have an API?
No public API is recorded for Oculis.
What industry is Oculis in?
Oculis's product category is Ophthalmic Biopharmaceuticals. Its primary akta.pro industry code is HLAKAKAE, Retina & Vitreous Specialists, with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 339115 and its SIC code is 3851.